Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Mondaycom Ltd (MNDY) Price & Performance

AstraZeneca plcTrade
Mondaycom LtdTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Mondaycom Ltd — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Mondaycom Ltd trades at $85.5 (market cap $3.70B). The key difference: AstraZeneca plc is far larger — about 67.1× Mondaycom Ltd's market cap, and AstraZeneca plc pays a 2.01% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals.

AZNMNDY
Market Cap
$248.14B$3.70B
Sector
HealthTechnology
52-Week High
$209.48$219.15
52-Week Low
$147.06$58.81
Enterprise Value
$275.41B$2.86B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.

Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.

Mondaycom Ltd

Monday.com (MNDY) trades at $85.95, down 3.01% amid mixed signals. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $1.48 versus $1.11 expected, and revenue growth of 22% year-over-year. However, weak Q3 revenue guidance has triggered a sell-off. Technical indicators are neutral with support at $83 and resistance at $89. Analyst consensus remains bullish with a $113.38 price target.

Outlook is cautiously optimistic due to robust earnings beats and AI product growth, but near-term risks include slower revenue guidance and competitive pressures. The high P/E of 37.04 suggests premium valuation, demanding sustained execution. Investors should weigh strong profitability against guidance concerns for balanced exposure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Mondaycom Ltd

Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.

Read more on MNDY